Richard Bergmark - Core Laboratories CFO, Executive VP and Supervisory Director

CLB
 Stock
  

USD 16.63  0.18  1.09%   

  Director
Mr. Richard L. Bergmark started serving as Executive Vice President of Core Laboratories N.V. on May 24, 2018, and resigned from this position as of December 31, 2018. He served as Chief Financial Officer, Member of the Board of Supervisory Directors of the Company between 2012 and May 24, 2018. He was Chief Executive Officer, Executive Vice President, Supervisory Director of the Company between March 2001 and 2012. He was Executive Vice President, Treasurer, Supervisory Director of the Company between 1999 and March 2001. He was Chief Financial Officer, Treasurer and Supervisory Director of the Company between 1995 and 1999. He was Chief Financial Officer, Treasurer of the Company between 1994 and 1995. Mr. Bergmark started serving as Supervisory Director since initial public offering in 1995. Mr. Bergmark joined Western Atlas International, Inc. as Treasurer in 1987. From 1987 to 1994, the Company was operated as a division of Western Atlas. In 1991, Mr. Bergmark became the Area Manager for Finance and Administration for Europe, Africa and the Middle East operations of Western Geophysical, a division of Western Atlas. From the separation with Western Atlas in 1994 until 1999, he served as the Chief Financial Officer and Treasurer and in 1999 he was appointed Executive Vice President.
Age: 61  Director Since 2018      
31 20 420 3191  https://www.corelab.com

Core Laboratories Management Efficiency

Core Laboratories has Return on Asset of 3.53 % which means that on every $100 spent on asset, it made $3.53 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 5.55 %, implying that it generated $5.55 on every 100 dollars invested. Core Laboratories management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 244.22 M in debt with debt to equity (D/E) ratio of 1.41, which is OK given its current industry classification. Core Laboratories has a current ratio of 2.04, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Core Laboratories until it has trouble settling it off, either with new capital or with free cash flow. So, Core Laboratories' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Core Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Core Laboratories to invest in growth at high rates of return. When we think about Core Laboratories' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

DIRECTOR Since

Wendell WeeksAmazon Inc
2016
John BrownAmazon Inc
2004
Patricia StonesiferAmazon Inc
2017
Jonathan RubinsteinAmazon Inc
2010
Judith McGrathAmazon Inc
2014
William GordonAmazon Inc
2003
Indra NooyiAmazon Inc
2019
Rosalind BrewerAmazon Inc
2019
Thomas RyderAmazon Inc
2011
Thomas AlbergAmazon Inc
2011
Tom AlbergAmazon Inc
2016
Jamie GorelickAmazon Inc
2012
Alain MonieAmazon Inc
2008
Daniel HuttenlocherAmazon Inc
2016
Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company was founded in 1936 and is based in Amstelveen, the Netherlands. Core Laboratories is traded on New York Stock Exchange in the United States. Core Laboratories NV (CLB) is traded on New York Stock Exchange in USA and employs 3,600 people.

Core Laboratories Leadership Team

Elected by the shareholders, the Core Laboratories' board of directors comprises two types of representatives: Core Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Core Laboratories. The board's role is to monitor Core Laboratories' management team and ensure that shareholders' interests are well served. Core Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Core Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Tahera Khan, Vice President Human Resources
Gwendolyn Schreffler, Senior Vice President, Corporate Development and Investor Relations
Lawrence Bruno, Chairman of the Supervisory Board, President, Chief Executive Officer, Chief Operating Officer
Monique Eeuwijk, Non-Executive Independent Member of the Supervisory Board
D Ogren, Member of the Supervisory Board
Michael Flecker, Vice President Production Enhancement
Christopher Hill, Chief Financial Officer, Senior Vice President
Alastair Crombie, Vice President Reservoir Description
Mark Elvig, Senior Vice President, Secretary, and General Counsel
Harvey Klingensmith, Non-Executive Independent Member of the Supervisory Board
Michael Straughen, Non-Executive Independent Member of the Supervisory Board
John Ogren, Member of the Supervisory Board
Charles Dunlap, Independent Member of the Board of Supervisory Directors
Monty Davis, COO and Sr. VP
David Hume, Vice President Reservoir Description
J Dumas, Vice President Business Development
Martha Carnes, Presiding Non-Executive Lead Independent Member of the Supervisory Board
Richard Bergmark, CFO, Executive VP and Supervisory Director
Kevin Daniels, Vice President, Chief Accounting Officer
James Gresham, Senior Vice President Business Development
David Demshur, Independent Chairman of the Board of Supervisory Directors and Chief Executive Officer
Kwaku Temeng, Non-Executive Independent Member of the Supervisory Board
Michael Kearney, Independent Supervisory Director
Peter Boks, Vice President Reservoir Description
Gregory Barnett, Non-Executive Independent Member of the Supervisory Board
Chris Hill, Chief Accounting Officer and VP
Margaret Kempen, Independent Member of the Board of Supervisory Directors
Lucia Geuns, Independent Member of the Board of Supervisory Directors
Jeffrey West, Vice President Production Enhancement
Mark Tattoli, Senior Vice President General Counsel, Secretary
Dumas, Vice President Business Development
Gwendolyn Gresham, Senior Vice President Corporate Development and Investor Relations
Jan Sodderland, Independent Member of the Board of Supervisory Directors

Core Laboratories Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Core Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Core Laboratories without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Pair Trading with Core Laboratories

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Core Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Core Laboratories will appreciate offsetting losses from the drop in the long position's value.

Moving together with Core Laboratories

+0.75HALHalliburton Upward RallyPairCorr
+0.74BKRBaker Hughes A Earnings Call  Next WeekPairCorr
The ability to find closely correlated positions to Core Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Core Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Core Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Core Laboratories NV to buy it.
The correlation of Core Laboratories is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Core Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Core Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Core Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. You can also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for analysis

When running Core Laboratories price analysis, check to measure Core Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Core Laboratories is operating at the current time. Most of Core Laboratories' value examination focuses on studying past and present price action to predict the probability of Core Laboratories' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Core Laboratories' price. Additionally, you may evaluate how the addition of Core Laboratories to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Is Core Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core Laboratories will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Core Laboratories is measured differently than its book value, which is the value of Core Laboratories that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine Core Laboratories value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.